140 related articles for article (PubMed ID: 8001635)
21. Opioid activity of C8813, a novel and potent opioid analgesic.
Liu ZH; Jin WQ; Dai QY; Chen XJ; Zhang HP; Chi ZQ
Life Sci; 2003 May; 73(2):233-41. PubMed ID: 12738037
[TBL] [Abstract][Full Text] [Related]
22. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
23. A series of novel, highly potent and selective agonists for the kappa-opioid receptor.
Hayes AG; Birch PJ; Hayward NJ; Sheehan MJ; Rogers H; Tyers MB; Judd DB; Scopes DI; Naylor A
Br J Pharmacol; 1990 Dec; 101(4):944-8. PubMed ID: 1964823
[TBL] [Abstract][Full Text] [Related]
24. The kappa-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs.
Brent PJ; Chahl LA; Cantarell PA; Kavanagh C
Eur J Pharmacol; 1993 Sep; 241(2-3):149-56. PubMed ID: 7902288
[TBL] [Abstract][Full Text] [Related]
25. ICI 204448: a kappa-opioid agonist with limited access to the CNS.
Shaw JS; Carroll JA; Alcock P; Main BG
Br J Pharmacol; 1989 Apr; 96(4):986-92. PubMed ID: 2568146
[TBL] [Abstract][Full Text] [Related]
26. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.
Vonvoigtlander PF; Lahti RA; Ludens JH
J Pharmacol Exp Ther; 1983 Jan; 224(1):7-12. PubMed ID: 6129321
[TBL] [Abstract][Full Text] [Related]
27. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies.
Kaneto H; Takahashi M; Watanabe J
J Pharmacobiodyn; 1990 Jul; 13(7):448-53. PubMed ID: 1963196
[TBL] [Abstract][Full Text] [Related]
28. Profile of activity of kappa receptor agonists in the rabbit vas deferens.
Hayes A; Kelly A
Eur J Pharmacol; 1985 Apr; 110(3):317-22. PubMed ID: 2988982
[TBL] [Abstract][Full Text] [Related]
29. Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid.
Vonvoigtlander PF; Lewis RA
J Pharmacol Exp Ther; 1988 Jul; 246(1):259-62. PubMed ID: 2839665
[TBL] [Abstract][Full Text] [Related]
30. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia.
Pick CG; Peter Y; Schreiber S; Weizman R
Brain Res; 1997 Jan; 744(1):41-6. PubMed ID: 9030411
[TBL] [Abstract][Full Text] [Related]
32. kappa-Opioid receptor agonist protects against ischemic reduction of 2-deoxyglucose uptake in morphine-tolerant rats.
Shibata S; Tominaga K; Watanabe S
Eur J Pharmacol; 1995 Jun; 279(2-3):197-202. PubMed ID: 7556401
[TBL] [Abstract][Full Text] [Related]
33. Withdrawal contractures of guinea-pig isolated ileum after acute activation of kappa-opioid receptors.
Morrone LA; Romanelli L; Amico MC; Valeri P
Br J Pharmacol; 1993 May; 109(1):48-52. PubMed ID: 8388301
[TBL] [Abstract][Full Text] [Related]
34. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
Capasso A; Sorrentino L; Pinto A
Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
[TBL] [Abstract][Full Text] [Related]
35. The antinociceptive activity of kappa- but not delta-opioid receptor agonists is maintained in morphine-tolerant neuropathic rats.
Catheline G; Kayser V; Idänpään-Heikkilä JJ; Guilbaud G
Eur J Pharmacol; 1996 Dec; 318(2-3):273-81. PubMed ID: 9016915
[TBL] [Abstract][Full Text] [Related]
36. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
Capasso A; Sorrentino L
Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
[TBL] [Abstract][Full Text] [Related]
37. Novel κ-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation.
Zhang LS; Wang J; Chen JC; Tao YM; Wang YH; Xu XJ; Chen J; Xu YG; Xi T; Hu XW; Wang YJ; Liu JG
Acta Pharmacol Sin; 2015 May; 36(5):565-71. PubMed ID: 25816912
[TBL] [Abstract][Full Text] [Related]
38. Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex inrat.
Diop L; Rivière PJ; Pascaud X; Junien JL
Eur J Pharmacol; 1994 Dec; 271(1):65-71. PubMed ID: 7698213
[TBL] [Abstract][Full Text] [Related]
39. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice.
Tsuji M; Yamazaki M; Takeda H; Matsumiya T; Nagase H; Tseng LF; Narita M; Suzuki T
Eur J Pharmacol; 2000 Apr; 394(1):91-5. PubMed ID: 10771039
[TBL] [Abstract][Full Text] [Related]
40. U-50,488 blocks the development of morphine tolerance and dependence at a very low dose in guinea pigs.
Tao PL; Hwang CL; Chen CY
Eur J Pharmacol; 1994 May; 256(3):281-6. PubMed ID: 8045272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
